Chieh-I Chen
Overview
Explore the profile of Chieh-I Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rofail D, Ciesluk A, Lovell T, Marquis P, Fury M, Chen C
Oncol Ther
. 2024 Oct;
12(4):803-815.
PMID: 39354264
Introduction: Although cutaneous squamous cell carcinoma (CSCC) is the second most common type of skin cancer, research describing the patient experience is limited. This study sought to create a conceptual...
2.
Oderda G, Brixner D, Biskupiak J, Harnett J, Chen C, Quek R
J Manag Care Spec Pharm
. 2024 Aug;
30(8):825-833.
PMID: 39088340
Background: There is limited knowledge of how US managed care professionals view and prioritize quality metrics/performance measures, care models, alternative payment models, and clinical pathways in oncology settings. Objective: To...
3.
Stratigos A, Chen C, Ivanescu C, Lewis K, Peris K, Bechter O, et al.
Future Oncol
. 2024 Jul;
20(30):2249-2258.
PMID: 39073799
To evaluate health-related quality of life (HRQoL) in cemiplimab-treated patients with locally advanced basal cell carcinoma (laBCC). Eighty-four patients with laBCC received cemiplimab 350 mg every 3 weeks (up to...
4.
Ge W, Wu N, Chen C, Inocencio T, LaFontaine P, Seebach F, et al.
Cancer Manag Res
. 2024 Jul;
16:841-854.
PMID: 39050978
Background: Prior to the Food and Drug Administration approval of cemiplimab in 2018, the median overall survival (OS) for adult patients with advanced CSCC receiving systemic therapy was approximately 8...
5.
Peris K, Inocencio T, Stratigos A, Lewis K, Eroglu Z, Chang A, et al.
Cancer Med
. 2024 Jul;
13(14):e7360.
PMID: 39031963
Background: A phase 2 cemiplimab study (NCT03132636) demonstrated a 24.1% objective response rate in patients diagnosed with metastatic basal cell carcinoma (mBCC) who were not candidates for continued hedgehog inhibitor...
6.
Chen C, Jalbert J, Wu N, Ruiz E
Future Oncol
. 2023 Nov;
20(11):691-701.
PMID: 37994593
Since use of major cutaneous surgeries/reconstructions among patients with cutaneous squamous cell carcinoma (CSCC) is not well described, we sought to quantify major cutaneous surgeries/reconstructions among patients with CSCC who...
7.
Stratigos A, Sekulic A, Peris K, Bechter O, Prey S, Lewis K, et al.
J Am Acad Dermatol
. 2023 Oct;
90(2):414-418.
PMID: 37839734
No abstract available.
8.
Konidaris G, Rofail D, Randall J, LaFontaine P, Chen C, Bury D, et al.
Dermatol Ther (Heidelb)
. 2023 Jun;
13(8):1747-1761.
PMID: 37330458
Introduction: Evidence of patients' experiences of living with advanced basal cell carcinoma (aBCC) are limited, particularly after hedgehog pathway inhibitor (HHI) treatment. We explored the burden of aBCC on symptoms...
9.
Song X, Chen C, Konidaris G, Zimmerman N, Ruiz E
Expert Rev Pharmacoecon Outcomes Res
. 2023 Jun;
23(8):911-920.
PMID: 37313647
Objectives: To describe real-world characteristics and treatment patterns of patients with metastatic cutaneous squamous cell carcinoma (mCSCC). Methods: This retrospective observational study used MarketScan Commercial and Medicare Supplemental claims databases...
10.
Cella D, Chen C, Quek R, Uribarren A, Reaney M, Mastey V, et al.
Front Pharmacol
. 2022 Nov;
13:1031992.
PMID: 36339622
Regulatory agencies encourage the incorporation of the patient voices throughout clinical drug development. Patient-Reported Outcomes (PROs) offer one way of doing this and their use has markedly increased in many...